Aditxt, Inc. extends merger agreement with Evofem Biosciences

Aditxt, Inc., a pharmaceutical company with a market capitalization of $2.27 million, has modified its merger plans with Evofem Biosciences (OTC:EVFM), Inc., according to a recent SEC filing. The latest amendment to their existing agreement, dated March 23, 2025, outlines new investment commitments and extends the deadline for the merger’s completion to September 30, 2025. InvestingPro analysis reveals the company faces significant financial challenges, with a concerning current ratio of 0.09 and negative EBITDA of $29.61 million.

The filing indicates that Aditxt has agreed to invest an additional $1.5 million into Evofem by April 7, 2025. This investment will be in exchange for more F-1 Preferred Stock or, if chosen by Aditxt, senior subordinated notes of Evofem. This is part of a series of investments tied to the merger agreement, which has seen several amendments since its initial filing on December 11, 2023. According to InvestingPro data, Aditxt’s revenue stands at just $0.21 million in the last twelve months, highlighting the significance of this investment commitment relative to its current operations.

The merger, initially proposed to create a combined entity under Aditxt’s ownership, has faced multiple adjustments over time. Previous amendments included changes to investment amounts and deadlines, reflecting ongoing negotiations and strategic planning between the two companies.

The merger is subject to shareholder approval, with Evofem expected to hold a shareholder meeting by September 26, 2025, to vote on the transaction. This timeline aligns with the newly set end date for the merger agreement.

Investors and market observers are keeping a close watch on the developments of this merger, which brings together two players in the pharmaceutical industry. The outcome of the shareholder meeting and the finalization of the merger are anticipated events that will shape the future of the companies involved. InvestingPro subscribers have access to 17 additional key insights about Aditxt’s financial health and market performance, essential for making informed investment decisions in this evolving situation.

This report is based on a press release statement and an SEC filing, which provides the official documentation of the merger agreement and its amendments.

In other recent news, Aditxt, Inc. has announced significant developments across its subsidiaries and strategic initiatives. The company is advancing its subsidiary Adimune’s drug candidate, ADI-100, which targets autoimmune diseases like Type I Diabetes and Psoriasis, with clinical trials planned in collaboration with the Mayo Clinic and German authorities. Pearsanta, another subsidiary, is preparing for an IPO with Dominari Securities LLC as the lead underwriter, aiming to fund its commercial launch of blood-based tests for early cancer detection. Adivue, following its acquisition of Brain Scientific, is working towards FDA approval for an EEG device.

Aditxt has also approved a 1-for-250 reverse stock split to comply with Nasdaq’s minimum bid price requirement, with the board finalizing the ratio and shareholders receiving one new share for every 250 shares owned prior. The company has extended its agreement with Appili Therapeutics and is in discussions with Evofem Biosciences regarding strategic integration. Additionally, Aditxt plans to launch weekly updates to enhance transparency with investors, featuring discussions from CEOs of Evofem and Aditxt. These developments highlight Aditxt’s ongoing efforts to advance its business objectives and health innovation initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.